Key result
Subjects in the highest tertile of serum betatrophin had significantly higher odds of having nonalcoholic fatty liver disease (OR 2.88; 95% CI 1.15-7.19; P<0.05).
Why the study?
Is serum betatrophin associated with the presence and severity of nonalcoholic fatty liver disease?
Cross-Sectional (n=249)
Is serum betatrophin associated with the presence and severity of nonalcoholic fatty liver disease?
Serum betatrophin is independently associated with liver fat content and may serve as a potential non-invasive marker for NAFLD.
Betatrophin measurement should not guide NAFLD care; leaves open its value as biomarker or target pending prospective studies.
OBJECTIVE: This study aimed to investigate the association of serum betatrophin with the status and progression of nonalcoholic fatty liver disease (NAFLD). METHODS: A total of 249 subjects who received ultrasonic examination of liver fat content (LFC) were recruited. Anthropometric and biochemical examinations were performed. Serum betatrophin was measured by ELISA. RESULTS: Compared with control group, serum betatrophin significantly increased in NAFLD group (P < 0.05). There was significant difference in serum betatrophin among control, low liver fat content (LLFC), and high liver fat content (HLFC) groups (P < 0.01). After adjustment for gender, age, BMI, FPG and HbA1c, the betatrophin positively correlated with LFC (r = 0.185, P < 0.01) and TG (r = 0.195, P < 0.01). Stepwise multiple regression analysis indicated serum betatrophin was independently related to LFC (P < 0.05). Multivariate logistic regression analysis revealed subjects in the highest tertile of serum betatrophin had higher odds of having NAFLD after adjustment for traditional NAFLD risk factors (OR = 2.88, 95%CI: 1.15-7.19) (P<0.05). CONCLUSION: Serum betatrophin is an independent risk factor for NAFLD and potential non-invasive marker for its progression. Serum betatrophin may be helpful for the early diagnosis of NAFLD and improvement of its prognosis.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2017) conducted a cross-sectional in Nonalcoholic fatty liver disease (NAFLD) (n=249). Serum betatrophin vs. Control group / lower tertiles was evaluated on Presence of NAFLD (OR 2.88, 95% CI 1.15-7.19, p=<0.05). Subjects in the highest tertile of serum betatrophin had significantly higher odds of having nonalcoholic fatty liver disease (OR 2.88; 95% CI 1.15-7.19; P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: